Why the study?
Does the live oral M37 human rotavirus vaccine provide clinical protection and immunogenicity in infants ages 2 to 6 months?
Does the live oral M37 human rotavirus vaccine provide clinical protection and immunogenicity in infants ages 2 to 6 months?
The M37 rotavirus vaccine at 10(4) PFU was inadequate for clinical protection, though the 10(5) PFU dose showed higher immunogenicity warranting further study.
No takes yet. Share an insight, caveat, or question.
M37 vaccine at 10(4) PFU confers no protection in infants; higher doses require efficacy trials before clinical use.
Vesikari et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: